260 related articles for article (PubMed ID: 23052129)
1. Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals.
Rotroff DM; Dix DJ; Houck KA; Knudsen TB; Martin MT; McLaurin KW; Reif DM; Crofton KM; Singh AV; Xia M; Huang R; Judson RS
Environ Health Perspect; 2013 Jan; 121(1):7-14. PubMed ID: 23052129
[TBL] [Abstract][Full Text] [Related]
2. Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model.
Browne P; Judson RS; Casey WM; Kleinstreuer NC; Thomas RS
Environ Sci Technol; 2015 Jul; 49(14):8804-14. PubMed ID: 26066997
[TBL] [Abstract][Full Text] [Related]
3. Assessing utility of thyroid in vitro screening assays through comparisons to observed impacts in vivo.
Eytcheson SA; Olker JH; Friedman KP; Hornung MW; Degitz SJ
Regul Toxicol Pharmacol; 2023 Oct; 144():105491. PubMed ID: 37666444
[TBL] [Abstract][Full Text] [Related]
4. Development, validation and integration of in silico models to identify androgen active chemicals.
Manganelli S; Roncaglioni A; Mansouri K; Judson RS; Benfenati E; Manganaro A; Ruiz P
Chemosphere; 2019 Apr; 220():204-215. PubMed ID: 30584954
[TBL] [Abstract][Full Text] [Related]
5. A predictive data-driven framework for endocrine prioritization: a triazole fungicide case study.
Paul Friedman K; Papineni S; Marty MS; Yi KD; Goetz AK; Rasoulpour RJ; Kwiatkowski P; Wolf DC; Blacker AM; Peffer RC
Crit Rev Toxicol; 2016 Oct; 46(9):785-833. PubMed ID: 27347635
[TBL] [Abstract][Full Text] [Related]
6. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
7. On selecting a minimal set of in vitro assays to reliably determine estrogen agonist activity.
Judson RS; Houck KA; Watt ED; Thomas RS
Regul Toxicol Pharmacol; 2017 Dec; 91():39-49. PubMed ID: 28993267
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
9. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
10. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
12. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
13. Weight of evidence for cross-species conservation of androgen receptor-based biological activity.
Vliet SMF; Markey KJ; Lynn SG; Adetona A; Fallacara D; Ceger P; Choksi N; Karmaus AL; Watson A; Ewans A; Daniel AB; Hamm J; Vitense K; Wolf KA; Thomas A; LaLone CA
Toxicol Sci; 2023 May; 193(2):131-145. PubMed ID: 37071731
[TBL] [Abstract][Full Text] [Related]
14. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
15. A novel framework for interpretation of data from the fish short-term reproduction assay (FSTRA) for the detection of endocrine-disrupting chemicals.
Ankley GT; Jensen KM
Environ Toxicol Chem; 2014 Nov; 33(11):2529-40. PubMed ID: 25098918
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate reference chemicals for in vitro steroidogenesis assays.
Pinto CL; Markey K; Dix D; Browne P
Toxicol In Vitro; 2018 Mar; 47():103-119. PubMed ID: 29146384
[TBL] [Abstract][Full Text] [Related]
17. Endocrine profiling and prioritization of environmental chemicals using ToxCast data.
Reif DM; Martin MT; Tan SW; Houck KA; Judson RS; Richard AM; Knudsen TB; Dix DJ; Kavlock RJ
Environ Health Perspect; 2010 Dec; 118(12):1714-20. PubMed ID: 20826373
[TBL] [Abstract][Full Text] [Related]
18. Toxicity testing and endocrine disrupting chemicals.
Vandenberg LN
Adv Pharmacol; 2021; 92():35-71. PubMed ID: 34452691
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Estrogenic Bioactivity of Environmental Chemical Metabolites.
Pinto CL; Mansouri K; Judson R; Browne P
Chem Res Toxicol; 2016 Sep; 29(9):1410-27. PubMed ID: 27509301
[TBL] [Abstract][Full Text] [Related]
20. Test driving ToxCast: endocrine profiling for 1858 chemicals included in phase II.
Filer D; Patisaul HB; Schug T; Reif D; Thayer K
Curr Opin Pharmacol; 2014 Dec; 19():145-52. PubMed ID: 25460227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
